Monthly Archives: February 2022

We reported in the previous Crohn’s and Colitis Congress and published in Refs 1 and 2 ,that a segment of 5 aa of a CD44 variant -Methionine, Threonine, Alanine, Aspartic Acid, Valine (MTADV), called 5-MER peptide (5MP), inhibits the inflammation in DS… Continue reading →

It’s a controversy if pancreatitis can be considered one of the extraintestinal manifestations of Crohn’s disease (CD). (Barthet et al AJG) CD patients have a fourfold increase in the risk of acute pancreatitis (AP) compared to the general population. … Continue reading →

To assess the surgical outcome in Crohn’s disease (CD) patients undergoing repeat ileocolic resection treated with biologic therapy prior to the surgical intervention. Continue reading →

Cardiac Complications are common in IBD. Myocarditis is a serious extraintestinal manifestation associated with inflammatory bowel disease. The aim of this study is to investigate the complications associated with myocarditis in patients who have IBD (… Continue reading →

A group of Inflammatory Bowel Disease (IBD) specialists have been utilizing a weekly live video conference “IBD Live” to discuss multidisciplinary management of challenging cases. Since 2009 the conference has featured robust interactive case discussio… Continue reading →

Approximately 4-23% of patients with IBD develop renal complications such as nephrolithiasis, glomerulonephritis, and tubulointerstitial nephritis, which may lead to chronic kidney disease (CKD). Furthermore, it has been shown that younger age of IBD d… Continue reading →

Poor sleep occurs in 75% of people with IBD and is prospectively associated with increased risk for disease flare, hospitalization, surgery, and reduced quality of life. While IBD providers know the link between poor sleep and IBD, few are adequately a… Continue reading →

Non-alcoholic fatty liver disease (NAFLD) is a spectrum that ranges from hepatic steatosis to Non-alcoholic steatohepatitis (NASH). NASH can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. (Chao CY et al. World J Gastroenterol). Both N… Continue reading →

In the search for alternative or supplemental treatment for Ulcerative Colitis (UC), we studied saffron (Crocus Sativus) in a UC clinical trial, as an additional intervention to improve clinical manifestations of UC through its anti-inflammatory and an… Continue reading →

Ulcerative colitis is a chronic, debilitating disease characterized by damage to the mucous membrane (mucosa) lining the lower gastrointestinal tract. Endoscopic and histological evidence of healing of the damaged mucosa, referred to as mucosal healing… Continue reading →